Design, synthesis, and antihypertensive activity of curcumin-inspired compounds via ACE inhibition and vasodilation, along with a bioavailability study for possible benefit in cardiovascular diseases

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 129-139

  Zhuang, Xiao Dong ^a   Liao, Li Zhen ^b   Dong, Xiao Bian ^a   Hu, Xun ^a   Guo, Yue ^a   Du, Zhi Min ^a   Liao, Xin Xue ^a   Wang, Li Chun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

ACE inhibition; Antihypertensive; Bioavailability; Curcumin; Synthesis; Vasodilation

Indexed keywords

1 BUTYL 3,5 BIS(3,4 DIHYDROXYBENZYLIDENE)PIPERIDIN 4 ONE; 1 BUTYL 3,5 BIS(3,4,5 TRIMETHOXYBENZYLIDENE)PIPERIDIN 4 ONE; 1 BUTYL 3,5 BIS(4 NITROBENZYLIDENE)PIPERIDIN 4 ONE; 1 ETHYL 3,5 BIS(3,4,5 TRIMETHOXYBENZYLIDENE)PIPERIDIN 4 ONE; 1 ETHYL 3,5 BIS(4 NITROBENZYLIDENE)PIPERIDIN 4 ONE; 1 PENTYL 3,5 BIS(3,4,5 TRIMETHOXYBENZYLIDENE)PIPERIDIN 4 ONE; 1 PROPYL 3,5 BIS(3,4,5 TRIMETHOXYBENZYLIDENE)PIPERIDIN 4 ONE; 3,5 BIS(3,4 DIHYDROXYBENZYLIDENE) 1 ETHYLPIPERIDIN 4 ONE; 3,5 BIS(3,4 DIHYDROXYBENZYLIDENE) 1 PROPYLPIPERIDIN 4 ONE; 3,5 BIS(4 NITROBENZYLIDENE) 1 PENTYLPIPERIDIN 4 ONE; 3,5 BIS(4 NITROBENZYLIDENE) 1 PROPYLPIPERIDIN 4 ONE; 3,5 DIBENZYLIDENE 1 BUTYLPIPERIDIN 4 ONE; 3,5 DIBENZYLIDENE 1 ETHYLPIPERIDIN 4 ONE; 3,5 DIBENZYLIDENE 1 PENTYLPIPERIDIN 4 ONE; 3,5 DIBENZYLIDENE 1 PROPYLPIPERIDIN 4 ONE; 5 BIS(3,4 DIHYDROXYBENZYLIDENE) 1 PENTYLPIPERIDIN 4 ONE; ANTIHYPERTENSIVE AGENT; CARDIOVASCULAR AGENT; CURCUMIN; UNCLASSIFIED DRUG; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; VASODILATOR AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HEART OUTPUT; HEART STROKE VOLUME; IC50; MOLECULAR DOCKING; MOUSE; NONHUMAN; RAT; SPECTROSCOPY; VASODILATATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; MALE; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; CARDIAC OUTPUT; CURCUMIN; FEMALE; INHIBITORY CONCENTRATION 50; LISINOPRIL; MALE; MICE; MOLECULAR DOCKING SIMULATION; RATS; RATS, WISTAR; STROKE VOLUME; VASODILATOR AGENTS;

EID: 84953857911     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S96315     Document Type: Article

References (19)

1. Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the Framingham heart study. Global Heart J. 2013;8(1): 49–57.
2. Burden: mortality, morbidity and risk factors. Available from: www.who.int/nmh/publications/ncd_report_chapter1.pdf. Accessed on July 28, 2015.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19): 2560–2572.
4. Borghi C, Rossi F. Role of the Renin-Angiotensin-Aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev. Epub September 24, 2015.
5. Sennesael J, Verbeelen D. Therapeutic efficacy and tolerance of two orally active angiotensin converting enzyme inhibitors in patients undergoing regular hemodialysis. Kidney Int. 1985;28:A252.
6. Davies MK, Gibbs CR, Lip GYH. Management: diuretics, ACE inhibitors, and nitrates. Br Med J. 2000;320(7232):428–431.
7. Osterziel KJ, Julius S. Vasodilators in the treatment of hypertension. Compr Ther. 1982;8(11):43–52.
8. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16: 4567–4598.
9. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94.
10. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
11. Košťálováa D, Bezákováb L, Račkovác L, Mošovskáa S, Šturdík E. Therapeutic potential of curcumin in medicinal chemistry. Acta Chim Slovaca. 2013;6(1):89–99.
12. Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146–157.
13. Ahmad W, Kumolosasi E, Jantan I, Bukhari SN, Jasamai M. Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2, cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1. Chem Biol Drug Des. 2014;83(6):670–681.
14. Bukhari SN, Lauro G, Jantan I, Bifulco G, Amjad MW. Pharmacological evaluation and docking studies of α, β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and proinflammatory cytokines. Bioorg Med Chem. 2014;22(15):4151–4161.
15. Bukhari SN, Jantan I, Unsal Tan O, Sher M, Naeem-Ul-Hassan M, Qin HL. Biological activity and molecular docking studies of curcumin-related α, β-unsaturated carbonyl-based synthetic compounds as anticancer agents and mushroom tyrosinase inhibitors. J Agric Food Chem. 2014;62(24): 5538–5547.
16. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005;2(2):131–136.
17. Bukhari SN, Butt AM, Amjad MW, Ahmad W, Shah VH, Trivedi AR. Synthesis and evaluation of chalcone analogues based pyrimidines as angiotensin converting enzyme inhibitors. Pak J Biol Sci. 2013;16(21): 1368–1372.
18. Addla D, Jallapally A, Kanwal A, Sridhar B, Banerjee SK, Kantevari S. Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors. Bioorg Med Chem. 2013;21(15): 4485–4493.
19. Skrzypiec-Spring M, Grotthus B, Szeląg A, Schulz R. Isolated heart perfusion according to Langendorff – still viable in the new millennium. J Pharmacal Toxicol Meth. 2007;55:113–126.